{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:27:31Z","timestamp":1785536851983,"version":"3.56.0"},"reference-count":46,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Form Res"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n One unique feature of COVID-19\u2013associated acute respiratory distress syndrome (ARDS) is surfactant deficiency because SARS-CoV-2 specifically attacks alveolar type 2 cells.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n In this study, we evaluated the effects of a synthetic surfactant (lucinactant) therapy in patients with COVID-19\u2013associated ARDS.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This open-label multicenter phase 1\/2A trial enrolled adult patients with COVID-19\u2013associated ARDS who were within 7 days of mechanical ventilation initiation. Lucinactant (160 mL or approximately 80 mg of total phospholipids per kilogram of lean body weight) was delivered intratracheally. One retreatment was allowed at \u22656-hour intervals. The primary end points were oxygenation index and PO\n 2<\/jats:sub>\n -to\u2013fraction of inspired oxygen ratio up to day 5 after dosing. Other end points included time to deliver lucinactant and respiratory system compliance (C\n rs<\/jats:sub>\n ). We monitored peridosing events and adverse events up to 30 days after dosing.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 19 treated patients were enrolled (n=14, 73.7% receiving 1 dose; n=5, 26.3% receiving 2 doses). The mean age was 49 (SD 15) years. The mean time to administer lucinactant was 31 minutes. No significant changes were observed in oxygenation index (mean 10.4, SD 5.8 at baseline; 8.6, SD 2.7 at 12 hours; and 5.7, SD 2.4 on day 5;\n P<\/jats:italic>\n =.12 via ANOVA) or PO\n 2<\/jats:sub>\n -to\u2013fraction of inspired oxygen ratio (mean 193, SD 69 at baseline; mean 179, SD 57 at 12 hours; and mean 223, SD 105 on day 5;\n P<\/jats:italic>\n =.44 via ANOVA). C\n rs<\/jats:sub>\n also did not change significantly (mean 40.7, SD 17.8 mL\/H\n 2<\/jats:sub>\n O at baseline; mean 33.6, SD 8.5 mL\/H\n 2<\/jats:sub>\n O at 12 hours; and mean 55.4, SD 18.5 mL\/cmH\n 2<\/jats:sub>\n O on day 5;\n P<\/jats:italic>\n =.12 via ANOVA). A total of 36.8% (n=7) of the participants died (6 from secondary infection and sepsis >13 days after dosing). In total, 15.8% (n=3) of the patients experienced transient peridosing desaturation or surfactant regurgitation.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Our study showed that intratracheal instillation of 1 to 2 doses of lucinactant in COVID-19\u2013associated ARDS was generally well tolerated. There were no significant changes in oxygenation parameters or C\n rs<\/jats:sub>\n . The data suggest that, when future studies of lucinactant in patients with ARDS with severe surfactant dysfunction are conducted, an earlier and longer treatment protocol using different delivery methods that reach a larger alveolar surface area, such as aerosolization, may be needed to yield any beneficiary effects.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/77315","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:20:08Z","timestamp":1760602808000},"page":"e77315-e77315","source":"Crossref","is-referenced-by-count":0,"title":["Lucinactant, a Synthetic Surfactant for the Treatment of Acute Respiratory Distress Syndrome Caused by COVID-19: Phase 1\/2A Trial"],"prefix":"10.2196","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0422-7259","authenticated-orcid":false,"given":"Yuh-Chin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9784-3032","authenticated-orcid":false,"given":"Peter","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6515-6204","authenticated-orcid":false,"given":"Robert","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6917-5511","authenticated-orcid":false,"given":"Carlos","family":"Guardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3870-9811","authenticated-orcid":false,"given":"Steven","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7048-7841","authenticated-orcid":false,"given":"Waldo","family":"Belloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1295-9145","authenticated-orcid":false,"given":"Lawrence","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4646-9509","authenticated-orcid":false,"given":"Phillip","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7956-2300","authenticated-orcid":false,"given":"Steven","family":"Simonson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"R1","unstructured":"WHO COVID-19 dashboard. World Health Organization. URL: https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c [Accessed 10-05-2025]"},{"issue":"18","key":"R2","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","journal-title":"N Engl J Med"},{"issue":"5","key":"R3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.14740\/jocmr4915","article-title":"The contribution of COVID-19 to acute respiratory distress syndrome-related mortality in the United States","volume":"15","author":"Oud","journal-title":"J Clin Med Res"},{"issue":"1","key":"R4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1056\/NEJM199501053320106","article-title":"The acute respiratory distress syndrome","volume":"332","author":"Kollef","journal-title":"N Engl J Med"},{"issue":"3 Pt 1","key":"R5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1164\/ajrccm.149.3.7509706","article-title":"The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination","volume":"149","author":"Bernard","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"R6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00134-020-06324-8","article-title":"COVID-19 and ARDS: the baby lung size matters","volume":"47","author":"Gattinoni","journal-title":"Intensive Care Med"},{"issue":"7","key":"R7","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1007\/s00134-020-06103-5","article-title":"The baby lung and the COVID-19 era","volume":"46","author":"Gattinoni","journal-title":"Intensive Care Med"},{"issue":"1","key":"R8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07944-4","article-title":"Reduced levels of pulmonary surfactant in COVID-19 ARDS","volume":"12","author":"Schousboe","journal-title":"Sci Rep"},{"issue":"1","key":"R9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/S2213-2600(20)30505-1","article-title":"Pathophysiology of COVID-19-associated acute respiratory distress syndrome","volume":"9","author":"Camporota","journal-title":"Lancet Respir Med"},{"issue":"S2","key":"R10","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.33549\/physiolres.934763","article-title":"Alveolar type II cells and pulmonary surfactant in COVID-19 era","volume":"70","author":"Calkovska","journal-title":"Physiol Res"},{"issue":"1","key":"R11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1164\/rccm.202201-0011OC","article-title":"Pulmonary surfactant proteins are inhibited by immunoglobulin a autoantibodies in severe COVID-19","volume":"207","author":"Sinnberg","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"R12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1378\/chest.105.1.195","article-title":"Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome","volume":"105","author":"Spragg","journal-title":"Chest"},{"issue":"4","key":"R13","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1164\/ajrccm.160.4.9808118","article-title":"Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome","volume":"160","author":"Wiswell","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"R14","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1056\/NEJMoa033181","article-title":"Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome","volume":"351","author":"Spragg","journal-title":"N Engl J Med"},{"issue":"8","key":"R15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1164\/rccm.201009-1424OC","article-title":"Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury","volume":"183","author":"Spragg","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"R16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1378\/chest.14-1139","article-title":"The adult calfactant in acute respiratory distress syndrome trial","volume":"148","author":"Willson","journal-title":"Chest"},{"issue":"2","key":"R17","doi-asserted-by":"publisher","DOI":"10.1186\/cc4851","article-title":"Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis","volume":"10","author":"Davidson","journal-title":"Crit Care"},{"issue":"1","key":"R18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000867","article-title":"Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an \u201cold\u201d strategy","volume":"8","author":"Bhatt","journal-title":"BMJ Open Respir Res"},{"issue":"8","key":"R19","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20230504","article-title":"Surfactant replacement therapy as promising treatment for COVID-19: an updated narrative review","volume":"43","author":"Khudadah","journal-title":"Biosci Rep"},{"issue":"1","key":"R20","doi-asserted-by":"publisher","first-page":"20946","DOI":"10.1038\/s41598-023-47672-x","article-title":"A randomized controlled trial of nebulized surfactant for the treatment of severe COVID-19 in adults (COVSurf trial)","volume":"13","author":"Dushianthan","journal-title":"Sci Rep"},{"issue":"5031","key":"R21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1126\/science.1948032","article-title":"Pulmonary surfactant protein B (SP-B): structure-function relationships","volume":"254","author":"Cochrane","journal-title":"Science"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.2165\/00042310-200521100-00002","article-title":"Lucinactant in neonatal respiratory distress syndrome: profile report","volume":"21","journal-title":"Drugs Ther Perspect"},{"issue":"4","key":"R23","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1542\/peds.2004-2183","article-title":"A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants","volume":"115","author":"Moya","journal-title":"Pediatrics"},{"issue":"4","key":"R24","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1542\/peds.2004-2231","article-title":"A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome","volume":"115","author":"Sinha","journal-title":"Pediatrics"},{"issue":"6","key":"R25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.siny.2009.08.002","article-title":"Prevention of bronchopulmonary dysplasia","volume":"14","author":"Laughon","journal-title":"Semin Fetal Neonatal Med"},{"issue":"6","key":"R26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/PCC.0b013e3182517bec","article-title":"A pilot, randomized, controlled clinical trial of lucinactant, a peptide-containing synthetic surfactant, in infants with acute hypoxemic respiratory failure","volume":"13","author":"Thomas","journal-title":"Pediatr Crit Care Med"},{"issue":"1","key":"R27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1164\/rccm.202208-1549ED","article-title":"Adding insult to injury: does COVID-19 promote acute respiratory distress syndrome by inhibiting surfactant?","volume":"207","author":"Richmond","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"R28","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1378\/chest.105.4.1263","article-title":"Successful treatment of ARDS with two doses of synthetic surfactant","volume":"105","author":"Heikinheimo","journal-title":"Chest"},{"issue":"3","key":"R29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/pl00022672","article-title":"The instillated surfactant in the treatment of sepsis-induced ARDS: case report","volume":"25","author":"Imperatore","journal-title":"Intensive Care Med"},{"issue":"1","key":"R30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/jam.1996.9.155","article-title":"Consensus on surfactant and inhaled nitric oxide for ARDS","volume":"9","author":"Gadek","journal-title":"J Aerosol Med"},{"issue":"7","key":"R31","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1136\/thx.2006.062398","article-title":"Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids","volume":"62","author":"Markart","journal-title":"Thorax"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2021.103645","article-title":"Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): role in SARS-CoV-2-related lung injury","volume":"288","author":"Cattel","journal-title":"Respir Physiol Neurobiol"},{"issue":"1","key":"R33","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.chest.2021.01.028","article-title":"Surfactant for the treatment of ARDS in a patient with COVID-19","volume":"160","author":"Heching","journal-title":"Chest"},{"issue":"6","key":"R34","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1203\/00006450-199606000-00004","article-title":"Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4","volume":"39","author":"Manalo","journal-title":"Pediatr Res"},{"issue":"1","key":"R35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/pl00007592","article-title":"Inhibitory effects of oxyradicals on surfactant function: utilizing in vitro Fenton reaction","volume":"176","author":"Amirkhanian","journal-title":"Lung"},{"issue":"Pt 1","key":"R36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1042\/bj2950019","article-title":"Reduction of the surface-tension-lowering ability of surfactant after exposure to hypochlorous acid","volume":"295 ( Pt 1)","author":"Merritt","journal-title":"Biochem J"},{"issue":"10","key":"R37","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/ppul.20468","article-title":"KL4-surfactant prevents hyperoxic and LPS-induced lung injury in mice","volume":"41","author":"Kinniry","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"R38","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ppul.21252","article-title":"Improved gas exchange and survival after KL-4 surfactant in newborn pigs with severe acute lung injury","volume":"45","author":"Zimmermann","journal-title":"Pediatr Pulmonol"},{"issue":"10300","key":"R39","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(21)00439-6","article-title":"Acute respiratory distress syndrome","volume":"398","author":"Meyer","journal-title":"Lancet"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1177\/1753466620951043","article-title":"Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia","volume":"14","author":"Busani","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"R41","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01603-w","article-title":"Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study","volume":"22","author":"Piva","journal-title":"Respir Res"},{"key":"R42","unstructured":"Randomized controlled phase II trial of poractant alfa (Curosurf\u00ae) by fiberoptic bronchoscopy-directed endobronchial administration in acute respiratory distress syndrome (ARDS) due to COVID-19 viral pneumonia. National Institutes of Health. 2021. URL: https:\/\/clinicaltrials.gov\/study\/NCT04384731 [Accessed 16-01-2026]"},{"key":"R43","unstructured":"Phase I\/II trial: exogenous surfactant administration for patients with COVID-19. National Institutes of Health. 2021. URL: https:\/\/clinicaltrials.gov\/study\/NCT04375735 [Accessed 16-01-2026]"},{"key":"R44","unstructured":"Multicenter, open-label, randomised trial to assess the efficacy and tolerability of poractant alfa(porcine surfactant, Curosurf\u00ae) in hospitalized patients with SARS-COV-19 acute respiratory distress syndrome (ARDS). National Institutes of Health. 2023. URL: https:\/\/clinicaltrials.gov\/study\/NCT04502433 [Accessed 16-01-2026]"},{"issue":"5","key":"R45","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00134-021-06394-2","article-title":"Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis","volume":"47","author":"Chaudhuri","journal-title":"Intensive Care Med"},{"issue":"4","key":"R46","first-page":"218","volume":"112","author":"Kula","journal-title":"Bratisl Lek Listy"}],"container-title":["JMIR Formative Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:56:41Z","timestamp":1785527801000},"score":1,"resource":{"primary":{"URL":"https:\/\/formative.jmir.org\/2026\/1\/e77315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":46,"URL":"https:\/\/doi.org\/10.2196\/77315","relation":{},"ISSN":["2561-326X"],"issn-type":[{"value":"2561-326X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"v10i18e77315"}}